Here, we show that PLP-CD8 swiftly ameliorated ongoing demyelinating disease and rapidly suppressed PLP-specific CD4 T cell responses by employing a temporally distinct cytokine effector program over a number of days in vivo. The gene discussed is CD8A; the disease is demyelinating disease.